Cargando…
Anti-VEGF Therapy in Breast and Lung Mouse Models of Cancers
Cancer is the second leading cause of death in the world after cardiovascular diseases. Some types of cancer cells often travel to other parts of the body through blood circulation or lymph vessels, where they begin to grow. This process is recognized as metastasis. Angiogenesis is the formation of...
Autores principales: | Marina, Di Domenico, Carmela, Ricciardi, Alfredo, Fusco, Giovanna Maria, Pierantoni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975084/ https://www.ncbi.nlm.nih.gov/pubmed/21076538 http://dx.doi.org/10.1155/2011/947928 |
Ejemplares similares
-
Tumor refractoriness to anti-VEGF therapy
por: Ribatti, Domenico
Publicado: (2016) -
Cytokines and VEGF Induction in Orthodontic Movement in Animal Models
por: Di Domenico, M., et al.
Publicado: (2012) -
Combination Therapy of VEGF-Trap and Gemcitabine Results in Improved Anti-Tumor Efficacy in a Mouse Lung Cancer Model
por: Zhou, Shuang, et al.
Publicado: (2013) -
E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression
por: Fedele, Monica, et al.
Publicado: (2006) -
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
por: Roland, Christina L., et al.
Publicado: (2009)